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doi:10.1016/j.ejvs.2009.09.027Abstract Objective: Since patients with peripheral arterial occlusive disease (PAOD) are at
high-risk for cardiovascular morbidity and mortality, preventive measures aimed to reduce
cardiovascular adverse events are advocated in the current guidelines. We conducted a system-
atic review to assess the implementation of secondary prevention (SP) measures in PAOD
patients.
Methods: PubMed, Cochrane Library, EMBASE and Web of Science databases were searched to
perform a systematic review of the literature from 1999 till June 2008 on SP for PAOD patients.
Assessment of study quality was done following the Cochrane Library review system. The
record outcomes were antiplatelet agents, heart rate lowering agents, blood pressure lowering
agents, lipid lowering agents, glucose lowering agents, smoking cessation and walking
exercise.
Results: From a total of 2137 identified studies, 83 observational studies met the inclusion
criteria, of which 24 were included in the systematic review comprising 34 157 patients. These
patients suffered from coronary artery disease (nZ 3516, 41%), myocardial infraction
(nZ 2647, 38%), angina pectoris (nZ 1790, 31%), congestive heart failure (nZ 2052, 14%),
diabetes mellitus (nZ 10 690, 31%),hypertension (nZ 20 823, 73%) and hyperlipidaemia
(nZ 15 067, 64%). Contrary to what the guidelines prescribe, antiplatelet agents, heart rateersity Medical Centre (LUMC), Department of Vascular Surgery, Albinusdreef 2 PO Box 9600, 2300 RC
umc.nl (J.H.P. Lardenoye).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Secondary Prevention, PAOD 71lowering agents, blood pressure lowering agents and lipid lowering agents were prescribed in
63%, 34%, 46% and 45% of the patients, respectively. Glucose lowering agents were prescribed
in 81% and smoking cessation in 39% of the patients.
Conclusion: The majority of patients suffering from PAOD do not receive the entire approach
of SP measures as suggested by the current guidelines. To our knowledge, the cause of this
undertreatment is multifactorial: patient, physician or health-care-related.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Peripheral arterial occlusive disease (PAOD) results from
the narrowing of blood vessels of the lower limbs,
predominantly secondary to atherosclerotic vascular
disease. Risk factors (RFs) associated with PAOD include
typical cardiovascular RFs, such as older age, smoking,
diabetes mellitus, hypercholesterolaemia and hyperten-
sion.1 PAOD is a substantial public health problem and is
also very common in the Western world. The first clinical
sign of PAOD is usually intermittent claudication (IC)2 and
increases dramatically with advancing age, ranging from
0.6% in individuals aged 45e54 years, to 8.8% in patients
aged 65e74 years.3,4
The aim of treatment of patients with PAOD is to
relieve lower extremity symptoms by interventions such
as regular walking exercise, endovascular therapy and/or
surgery. However, besides therapeutic strategies aimed
at relief of compromised flow to the lower limb, reduc-
tion of the risk of future cardiovascular events in this
specific high-risk patient population is of utmost
importance.
Secondary prevention (SP) aims to minimise the risk of
vascular morbidity and mortality and requires major
changes in lifestyle, such as smoking cessation4 and
medical treatment with antiplatelet agents (APAs),5,6,7
lipid lowering agents (LLAs),7,8,9 heart rate lowering
agents (HRLAs)7,10,11,12 and blood pressure lowering
agents (BPLAs)7,13,14,15 that should be continued lifelong.
There is substantial evidence that a combination of long-
term, tailored medical treatment in combination with
lifestyle adjustments is beneficial in the reduction of
future adverse cardiovascular events in these PAOD
patients.13,14,15
Effective SP is outlined in recent guidelines such as the
‘Trans-Atlantic Inter-Society Consensus Document on
Management of Peripheral Arterial Disease (TASC I and II)’
reporting standards13,14 and the guidelines for the preven-
tion of cardiovascular events in patients with symptomatic
PAOD proposed by the American Heart Association/Amer-
ican College of Cardiology (AHA/ACC).15 Although PAOD
patients would benefit from aggressive SP, as stated in the
TASC and AHA/ACC guidelines, the actual prevalence of
these preventative measures in this specific patient
population is unknown.
Therefore, we conducted a systematic review to assess
the implementation/prevalence of established recom-
mended SP measures by physicians in patients with
intermittent claudication (IC) or critical limb ischaemia
(CLI) using recent literature16e39 concerning imple-
mentation of established recommended SP in PAOD
patients.Materials and Methods
Search strategy
A systematic search of literature was performed in the
medical databases PubMed, Cochrane Library, EMBASE and
Web of Science. The search strategy used for each database
is described in the Appendices 1e4, respectively. In addi-
tion, we manually searched the reference lists of relevant
articles to identify articles missed by electronic searches.
Language was restricted to English, French, German and
Dutch. We did not systematically search abstract books of
conference proceedings, did not handesearch leading
journals and did not contact leading authors in the field to
retrieve potential extra papers.
Inclusion criteria
The inclusion criteria of the studies for the systematic
review are listed in Appendix 5.
Types of studies
Any prospective or retrospective study evaluating the
evidenced-based medicine along with guideline-concor-
dance of SP in patients with PAOD was considered. The
studies had to be published from 1999 (the year of the TASC
I13 reporting guidelines) till June 2008. They had to describe
an original patient series evaluating the SP in PAOD
patients. Studies had to describe a consecutive patient
series and had to comprise a minimal number of 40 patients
to be eligible for inclusion.
Participants, risk factors, co-morbidity and secondary
prevention
Studies were eligible if they evaluated patients with PAOD:
intermittent claudication (IC) or critical lower limb
ischaemia (CLI) according to the Society of Vascular
Surgery/North American Chapter of the International
Society for Cardiovascular Surgery (SVS/ISCVS).40 As listed
in Tables 1e3, risk factors (RFs), co-morbidity and
SP5e12,41e44 were registered for all evaluated studies.
Study selection
Titles and/or abstracts of all selected manuscripts in the
initial search were screened by two reviewers (HF and JL)
independently to identify potentially relevant articles, using
the inclusion criteria and using a standardised form.
Table 1 Study characteristics of the evaluated literature16e39 in this study.
No Ref Author Journal of
Publication
Year of
Publication
Midpoint
of Study
Countryof
Origin
Patients Mean
age
years
Male
Gender
Study Design PAOD Type of treatment
1. 16. Anand CJC 1999 1997 Canada 195 (1) 71 119 (61) retrospective IC and CLI Revascularization (S),
major amputation
2. 17. Hirsch JAMA 2001 1999 USA 1865 (5) 70 895 (48) prospective IC Control outpatient clinic
3. 18. Bismuth EJVES 2001 1998 Denmark 147 (0) 76 82 (56) retrospective CLI Revascularization (S)
4. 19. Nass Vasc Med 2001 1997 USA 155 (0) 69 81 (52) retrospective IC and CLI Revascularization (S)
5. 20. Burns EJVES 2002 NR UK 150 (0) NR NR retrospective IC Revascularization (Eþ S)
6. 21. Cassar EJVES 2003 2001 UK 104 (0) 70 57 (55) retrospective IC Control outpatient clinic
7. 22. Torella Surgeon 2003 1999 UK 89 (0) 68 67 (75) retrospective IC Conservative
8. 23. Henke JVS 2004 2000 USA 293 (1) 64 196 (67) retrospective IC and CLI Revascularization (S)
9. 24. Rehring JVS 2005 2003 USA 1733 (5) NR NR retrospective IC Revascularization (S)
10. 25. Conte JVS 2005 2002 USA 1404 (4) 69 899 (64) retrospective CLI Revascularization (S)
11. 26. Okaa Vasc Med 2005 2001 USA 101 (0) 73 74 (73) retrospective IC Control outpatient clinic
12. 27. Ness JGABSMS 2005 2004 USA 209 (1) 72 102 (49) retrospective IC Revascularization (S)
13. 28. Dedola AMCV 2005 2000 France 5708 (17) 65 4623 (81) retrospective IC and CLI Control outpatient clinic
14. 29. Barani Int Angiol 2005 2001 Sweden 259 (1) 75 138 (53) prospective CLI Control outpatient clinic
15. 30. Bhatt JAMA 2006 2004 USA 8273 (24) 69 5874 (71) prospective IC and CLI Control outpatient clinic
16. 31. Bradley EJVES 2006 2004 UK 109 (0) 70 78 (72) retrospective CLI Major amputation
17. 32. Bianchi AVS 2007 2006 USA 167 (0) 68 NR retrospective IC and CLI Control outpatient
clinic after revascularization (Eþ S)
18. 33. Khan EJVES 2007 2003 UK 473 (1) 68 317 (67) prospective IC Control outpatient clinic
19. 34. Wilson EJVES 2007 2005 UK 213 (1) 68 138 (65) prospective IC Control outpatient clinic
20. 35. Hasimu Circ J 2007 NR China 5254 (15) 67 2785 (53) retrospective IC and CLI Revascularization (Eþ S),
major amputation
21. 36. Dunkley PMJ 2007 2005 UK 103 (0) 73 64 (62) retrospective IC and CLI Control outpatient clinic
22. 37. Gasse EJVES 2008 2000 Denmark 4592 (13) 72 2362 (51) retrospective IC and CLI Revascularization (S)
23. 38. Makowsky AHJ 2008 2002 Canada 2509 (7) 69 1806 (72) prospective IC and CLI Revascularization (Eþ S),
major amputation
24. 39. Janes BJC 2008 2003 UK 52 (0) 73 31 (60) prospective IC and CLI Revascularization (S)
34157 67 20789 (65)
Data are presented as n and (%), unless otherwise specified. NoZ number; RefZ reference; CJCZ The Canadian Journal of Cardiology; JAMAZ The Journal of the American Medical
Association; EJVESZ European Journal of Vascular and Endovascular Surgery; Vasc MedZ Vascular Medicine; ANZJSZ New Zeeland Journal of Surgery; JCEZ Journal of Clinical
Excellence; JVSZ Journal of Vascular Surgery; JGABSMSZ The Journals of Gerontology: Biological Sciences and Medical Sciences; AMCVZ Arch Mal Coeur Vaiss; Int AngiolZ Internal
Angiology; AVSZ Annals of Vascular Surgery; Circ JZ Circulation Journal; PMJZ Postgrad Medical Journal; AHJZ American Heart Journal; BJCZ British Journal of Cardiology; NRZ not
reported/not possible to retrieve data; SZ surgical; EZ endovascular.
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Table 2 Cardiovascular/atherosclerosis risk factors in PAOD patients of the evaluated literature16e39 in this study.
Ref Author DM HT HL CAD MI AP AR CHF CABG PCI SMO CVD
16. Anand 74 (38) 97 (50) 35 (18) 106 (54) 66 (34) 58 (30) NR NR 18 (9) NR 134 (69) 38 (19)
17. Hirsch 770 (41) 628 (87) 1214 (65) NR 456 (24) 530 (28) NR 290 (16) 380 (20) 244 (13) 1173 (63) 365 (20)
18. Bismuth 38 (26) 96 (65) NR NR 25 (17) 21 (14) 37 (25) 18 (12) 3 (2) NR 112 (76) 25 (17)
19. Nass 72 46) 86 (55) NR NR 63 (41) NR NR 95 (61) NR NR 123 (79) NR
20. Burns 80 (53) NR 33 (22) 16 (24) NR NR NR NR NR NR 105 (70) NR
21. Cassar 30 (29) NR NR NR NR NR NR NR NR NR 40 (38) NR
22. Torella 16 (18) 52 (58) 47 (53) NR 44 (49) 41 (46) NR NR NR NR NR NR
23. Henke 155 (53) 205 (70) 142 (48) 149 (51) NR NR NR 41 (14) 53 (18) 29 (10) 88 (30) 38 (13)
24. Rehring 414 (24) 970 (56) 1085 (63) NR NR NR NR NR NR NR NR NR
25. Conte 899 (64) 1151 (82) 772 (55) 646 (46) 421 (30) NR NR NR 351 (25) 239 (17) 1039 (74) 281 (20)
26. Oka 27 (27) 55 (54) 57 (56) 49 (49) NR 38 (38) NR 13 (13) NR NR 77 (76) 13 (13)
27. Ness 94 (45) 188 (90) 184 (88) 132 (63) NR NR NR NR NR NR 148 (71) 75 (36)
28. Dedola 1313 (23) 3596 (63) 3539 (62) 2226 (39) NR NR NR NR NR NR 4053 (71) 514 (9)
29. Barani 123 (47) 181 (70) 165 (64) NR NR 122 (47) NR NR NR NR 156 (60) NR
30. Bhatt 3640 (44) 6701 (81) 5543 (67) NR NR NR NR NR NR NR 6205 (75) NR
31. Bradley NR NR NR NR NR NR NR NR NR NR NR NR
32. Bianchi 92 (55) 135 (81) 110 (66) NR NR NR NR NR NR NR 73 (44) NR
33. Khan 96 (20) 265 (56) 206 (44) 141 (30) 69 (15) 87 (18) NR NR 44 (9) 17 (4) 406 (86) 35 (7)
34. Wilson 48 (23) 138 (65) 89 (42) NR NR NR NR NR NR NR 81 (38) NR
35. Hasimu 716 (14) NR NR NR NR NR NR 408 (8) NR NR NR 661 (13)
36. Dunkley 30 (29) 71 (69) NR 51 (50) 19 (18) 32 (31) 12 (12) NR NR NR 81 (79) 23 (22)
37. Gasse 1090 (24) 3283 (71) NR NR NR NR NR 507 (11) NR NR NR 757 (16)
38. Makowsky 855 (34) 1895 (76) 1845 (74) NR 1484 (59) 861 (34) NR 680 (27) 242 (10) 205 (8) 858 (34) 677 (27)
39. Janes 19 (37) 28 (54) NR NR NR NR NR NR NR NR NR NR
Total evaluated 34048 (99) 28540 (84) 23641 (69) 8636 (25) 6940 (20) 5741 (17) 250 (1) 14916 (44) 6886 (20) 6544 (19) 22328 (65) 22853 (67)
Diagnosed with 10690 (31) 20823 (73) 15067 (64) 3516 (41) 2647 (38) 1790 (31) 49 (20) 2052 (14) 1190 (16) 734 (11) 14952 (67) 3502 (15)
Data are presented as n and (%), unless otherwise specified. PAODZ peripheral arterial occlusive disease; RefZ reference; DMZ diabetes mellitus; HTZ hypertension; HLZ hyperli-
pidaemia; CADZ coronary arterial disease; MIZmyocardial infraction; APZ angina pectoris; ARZ arrhythmia; CHFZ congestive heart failure; CABGZ coronary artery bypass graft;
PCIZ percutaneous coronary intervention; SMOZ smoking; CVDZ cerebrovascular disease; NRZ not reported/not possible to retrieve data.
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Table 3 Review of implementation of established recommended secondary prevention measures in patients with PAOD of the
evaluated literature16e39 in this study.
Ref Author Walking
exercise
Smoking
cessation
Glucose
lowering
agent
Lipid lowering
medication
Antiplatelet
agent
Heart rate
lowering agent
Blood pressure
lowering agent
16. Anand NR NR 68 (92) 31 (16) 73 (37) 39 (20) NR
17. Hirsch NR 532 (45) 644 (84) 773 (41) 1223 (60) NR NR
18. Bismuth NR NR NR 8 (5) 70 (48) 17 (12) 38 (40)
19. Nass NR NR NR 47 (30) 69 (45) 40 (26) 58 (67)
20. Burns 24 (16) 23 (15) 38 (48) 57 (38) 105 (70) NR NR
21. Cassar 15 (14) 34 (85) 18 (60) 39 (38) 75 (72) NR NR
22. Torella NR NR NR 29 (33) 61 (69) NI NR
23. Henke NR NR NR 164 (56) 272 (93) 202 (69) 137 (67)
24. Rehring NR NR 166 (40) 543 (31) 87 (5) 574 (33) 281 (29)
25. Conte NR NR NR 646 (46) 941 (67) 674 (48) NR
26. Oka 55 (54) 1 (1) 9 (33) 39 (39) 63 (62) NI NR
27. Ness NR NR NR 140 (67) 178 (85) 130 (62) NR
28. Dedola NR NR NR 2569 (45) 4509 (79) 1256 (22) NR
29. Barani NR NR NR 61 (24) 180 (69) NRþNI 97 (54)
30. Bhatt NR NR 3094 (85) 5791 (70) 6784 (82) 3557 (43) 3150 (47)
31. Bradley NR NR NR 51 (47) 65 (60) NR NR
32. Bianchi NR NR 92 (100) 88 (53) 115 (69) 70 (42) 96 (71)
33. Khan NR 37 (9) 84 (88) 212 (45) 335 (71) NI 123 (46)
34. Wilson 4 (2) 65 (80) NR 132 (62) 34 (16) NRþNI NR
35. Hasimu NR NR NR 1891 (36) 3047 (58) NR NR
36. Dunkley 58 (56) 78 (96) NR 70 (68) 91 (88) NI NR
37. Gasse NR NR NR 489 (11) 1248 (27) 622 (14) 1027 (31)
38. Makowsky NR NR NR 1340 (53) 2085 (83) 1569 (63) 1321 (70)
39. Janes NR NR NR 17 (33) 25 (48) NR 12 (43)
aTotal evaluated 671 (2) 1963 (6) 5223 (15) 34157 (100) 34157 (100) 25385 (74) 13846 (66)
bDiagnosed with 155 (23) 762 (39) 4213 (81) 15227 (45) 12635 (63) 8750 (34) 6340 (46)
Data are presented as n and (%), unless otherwise specified. PAODZ peripheral arterial occlusive disease. RefZ reference; NRZ not
reported/not possible to retrieve data; NIZ not included because of non-invasive treatment; TASCZ Trans-Atlantic Inter-Society
Consensus Document on Management of Peripheral Arterial Disease reporting standards; AHA/ACCZ American Heart Association/
American College of Cardiology. Smoking cessationZ all smoking PAOD patients who were prescribed/advised with smoking cessation.
Glucose lowering agentsZ only the PAOD patients diagnosed with diabetes mellitus and indicated for glucose lowering treatment were
included. Lipid lowering medication and antiplatelet agentsZ according to the TASC I and II13,14 and AHA/ACC reporting guidelines15,
all PAOD should be treated with both of these agents. Heart rate lowering agentZ only the PAOD patients after invasive treatment by
revascularization (endovascular, surgical) or with a major amputation (below knee - or above knee) were included. Blood pressure
lowering agentZ only the PAOD patients diagnosed with hypertension indicated for prescription of antihypertensive medications were
included.
a Total of patients actual evaluated in the literature.
b Total of patients prescribed with the concerning SP of the actual evaluated total patients in the literature.
74 H.C. Flu et al.Discrepancies in judgement were resolved after discussion
and, when necessary, after mediation of a third reviewer
(JH). The full text of these articles was retrieved for further
analysis.
Study quality and data extraction
Studies fulfilling all inclusion criteria were checked on
study quality characteristics by two reviewers (HF and
JL), independently. Assessment of study quality was done
using a form based on a checklist of the Cochrane
Library.45Registration and statistical analysis
Statistical analyses were performed with Excel (Office XP
from Microsoft Corp., WA, USA) and SPSS 16.0 for Windows
(SPSS Inc., Chicago, IL, USA).
Results
Study selection
The search identified 2137 potentially eligible studies of
which 2055 were excluded based on title and abstract.
Combined search results of 4 databases
2137 publications
83 publications selected on title and 
abstract
29 full-text articles included in 
systematic review
24 full-text articles eligible for 
systematic review
5 similar databases 
5 no consecutive series 
7 data inadequate 
or data not retrievable
9 questionnaires sent to 
physicians (GP, VS, VI, CA)
33 including AAA and carotid 
surgery
Figure 1 Study flow and exclusion criteria. GPZ general practitioner; VSZ vascular surgeon; VIZ vascular internist;
CAZ cardiologist.
Secondary Prevention, PAOD 75From the remaining 83 studies, full articles were collected
and evaluated. Twenty-four articles met our inclusion
criteria and were included in the systematic review. Study
flow and reasons for exclusion are presented in Fig. 1.Study descriptions
Characteristics of the included articles are shown in Tables
1 and 2. These articles represented 34 157 patients diag-
nosed with PAOD over a period of 10 years. Only seven
studies (29%) were prospective and 17 studies (71%) were
retrospective.
Patient characteristics
As listed in Table 1, a total of 20 789 men (65%) and 13 368
women (35%) were evaluated, with a mean age of 70 years
(range 64e76). They suffered from coronary artery disease
(nZ 3516; 41%), myocardial infraction (nZ 2647; 38%),
angina pectoris (nZ 1790; 31%), congestive heart failure
(nZ 2052; 14%), diabetes mellitus (nZ 10 690; 31%)hypertension (nZ 20 823; 73%) and hyperlipidaemia
(nZ 15 067; 64%). A total of 67% of the patients (nZ 14
952) were current smokers.
Secondary prevention
As listed in Tables 2 and 3 and Fig. 2aee, a minority of
the PAOD patients received proper SP. Contrary to what
the guidelines prescribe, about 45% (nZ 15 227; range
5e70%) of the patients were treated with LLA, 63%
(nZ 21 657; range 5e88%) of all patients were treated
with APA, 34% (nZ 8750; range 12e69%) of the PAOD
patients (treated with revascularisation or major ampu-
tation) were treated with HRLA and 46% (nZ 6340; range
29e71%) of all patients with hypertension were treated
with BPLA. A total of 81% of the patients with diabetes
mellitus with indication for treatment (nZ 4213; range
33e100%) were treated with glucose lowering agents
(GLAs), 39% of the current smokers (nZ 762; range 1e
96%) were advised on smoking cessation and 23% of the IC
patients (nZ 155, range 2e56%) were prescribed walking
exercise.
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Figure 2 (a) Percentage of patients actually treated with lipid lowering agents in the evaluated in the literature16e39, Data
are presented as %, The bottom numbers of the bar graph are the corresponding reference numbers (30, 36, 27, 34, 23, 38, 32,
31, 25, 28, 33, 17, 26, 20, 21, 35, 22, 39, 24, 19, 29, 16, 37 and 18), (b) Percentage of patients actually treated with antiplatelet
agents in the evaluated in the literature16e39, Data are presented as %, The bottom numbers of the bar graph are the corre-
sponding reference numbers (20, 36, 27, 38, 30, 28, 34, 21, 33, 20, 29, 32, 22, 25, 26, 17, 31, 35, 16, 39, 18, 19, 37 and 24). (c)
Percentage of patients actually treated with blood pressure lowering agents in the evaluated in the literature16e39, Data are
presented as %, The bottom numbers of the bar graph are the corresponding reference numbers (38, 19, 23, 32, 29, 30, 33, 39,
18, 37, 24). (d) Percentage of patients actually treated with heart rate lowering agents in the evaluated in the literature16e39,
Data are presented as %, The bottom numbers of the bar graph are the corresponding reference numbers (36, 23, 38, 27, 25, 30,
32, 24, 22, 19, 28, 16, 33, 37 and 18). (e) Percentage of patients actually treated with antiplatelet agents, blood pressure
lowering agents, lipid lowering agent and heart rate lowering agents in the evaluated in the literature16e39 from 1997 till 2007,
Data are presented as %, APAZ antiplatelet agents; BPLAZ blood pressure lowering agents; LLAZ lipid lowering agent;
HRLAZ heart rate lowering agent.
76 H.C. Flu et al.Discussion
In this study, we describe a high prevalence of modifiable
risk factors for cardiovascular disease in patients suffering
from PAOD (IC and CLI) and a disappointing level of
implementation of SP measures to reduce cardiovascular
events in this specific high-risk patient group. These
conclusions are the results of a systematic review of recent
literature concerning SP in PAOD patients in vascular
surgery because of IC or CLI.
PAOD is not only a manifestation of extensive athero-
sclerosis but also a marker of increased risk for coronary
and cerebrovascular complications including death. Giventhe high baseline risk of this population and the effec-
tiveness of SP,14,15,46 a combination of multiple drug ther-
apies, in combination with aggressive lifestyle change and
revascularisation, can substantially reduce the burden of
morbidity and mortality in patients with PAOD. Most
patients with PAOD substantially benefit from aggressive
medical therapy.47 Optimal SP reduces the risk of
revascularisation; it can improve functional status and
quality of life in the long-term and is cost-effective. These
approaches are expected to produce a cumulative relative
risk reduction of approximately 75%.48
SP is recommended in evidence-based guidelines for the
prevention of cardiovascular events in patients with PAOD
Secondary Prevention, PAOD 77as proposed in the AHA/ACC e and TASC I and II reporting
guidelines and several other evidence-based recommen-
dations. However, the implementation of the updated and
revised AHA/ACC or TASC I and II reporting guidelines is
unknown. In this systematic review of predefined specific
studies evaluating SP, a substantial gap between recom-
mendations in guidelines and actual clinical practice in the
care of PAOD patients is demonstrated. Only a minority of
patients were at AHA/ACC or TASC I and II guideline target
goals for SP.
Lifestyle adjustments concerning SP
Although detailed analysis of prevalence of smoking was
not described in all evaluated studies, only 39% of regis-
tered smokers entered a smoking cessation programme.
Smoking is associated with PAOD severity, an increased
risk of amputation, peripheral graft occlusion and
mortality in PAOD patients.49 All patients who smoke
should strongly and repeatedly be advised to stop smoking
and should receive a programme of physician advice,
group-counselling sessions and nicotine replacement.
Although detailed analysis of prevalence of walking exer-
cise was not described in all evaluated studies, only 23% of
the patients entered a walking exercise programme. These
programmes improve functional performance and alter
cardiovascular risk.50,51 IIt is important to stress that
supervised exercise therapy has statistically significant
benefits on treadmill-walking distance compared with non-
supervised regimens, which is currently the main
prescribed exercise therapy for people with intermittent
claudication.52
Medical treatment concerning SP
Antiplatelet agents
Detailed analysis of prevalence of prescribed APA was
described in all evaluated studies; only 63% of all PAOD
patients were prescribed with an APA. The use of APA is
indicated as secondary cardiovascular prevention in
patients presenting with PAOD. All symptomatic PAOD
patients with or without a history of other cardiovascular
disease should be prescribed APA long-term to reduce the
risk of cardiovascular morbidity and mortality. Patients who
withdraw APA prior to the event have worse outcomes than
those who either continued on APA or those who have never
received APA.5e7,46
Blood pressure and heart rate regulation
Although detailed analysis of prevalence of prescribed
antihypertensive medication is not described in all evalu-
ated studies, only 34% of all PAOD patients were prescribed
with HRLA and 46% of the patients were treated with BPLA.
The interpretation of this intensity of medical treatment
with these agents is not straightforward. First, control of
hypertension is essential for the prevention of stroke,
myocardial infarction and congestive heart failure in
hypertensive patients and in patients at increased cardio-
vascular risk including presence of PAOD (HOPE trial).53 In
this systematic review, 73% of the patients were found to
have hypertension. Most of these patients will needmedical therapy in addition to lifestyle treatment.
However, these subjects are not uncomplicated hyperten-
sive patients but patients with hypertension and clinically
evident PAOD, thereby defining them as high-risk to very
high-risk patients for recurrent cardiovascular events and
death due to those events.Blood pressure lowering agents
In this setting, it is important to recall studies such as the
HOPE trial 53 ; it makes the case for the beneficial effect of
ACEi (ramipril) in PAOD patients, and the ABCD trial54
(enalapril); illustrating these effects for diabetic patients in
the latest guidelines.55
For the management of patients with PAOD, ACEi may be
considered for cardiovascular risk reduction. They are
recommended for the treatment of left ventricular
dysfunction and patient wellbeing by reducing in-hospital
stay and increasing patient survival.56 Patients with
asymptomatic systolic left ventricular dysfunction (left
ventricular ejection fraction <40%) should receive ACEi
treatment. Patients with asymptomatic systolic left
ventricular dysfunction (left ventricular ejection fraction
<40%) and myocardial infarction in past history should
receive b-blockers as well for improvement of left
ventricular function and heart rate control.Heart rate regulation lowering agents
In the DECREASE-I trial,57 treatment with the highly b-1
selective b-blocker bisoprolol was initiated at least 30 days
prior to surgery and, to maximise beneficial effects,
patients were titrated according to tolerance to achieve
heart rate control between 65 and 70 beats per minute
(bpm).57 In the literature, it is suggested that the long-term
beneficial effects of b-blocker therapy might be explained
by a decrease of progress of coronary atherosclerosis.58 In
contrast to the instant effect on heart rate control as
demonstrated in the DECREASE-1 trial, the effect of
b-blockers on plaque stabilisation may therefore be
achieved only after prolonged treatment. The latest AHA/
ACC guidelines on perioperatively heart rate regulation
initiated b-blocker treatment in patients with one or more
cardiovascular clinical risk factors to achieve perioperative
heart rate between 65 and 70 bpm.59Lipid lowering agents
LLAs, especially statins, have been shown to dramatically
improve outcome of subjects with proven atherosclerotic
cardiovascular disease (HPS trial).60 This was observed
for many primary and secondary outcome measures,
including cardiovascular mortality. Subgroup analysis
showed PAOD patients benefited from statin treatment
similar to all other secondary and primary prevention
patients studied. Accordingly, most, if not all, guidelines
recommend treatment with statins in all SP patients
including PAOD patients. In our review, we found
detailed analysis of prevalence of prescribed LLA in all
evaluated studies; only 53% of all PAOD patients were
prescribed statins or other LLA, clearly making the point
for further improvement. Of note, the specific impact of
LLA on PAOD-related vessel changes and improvement of
78 H.C. Flu et al.clinical presentations is less well studied. However,
favourable influences on leg functioning, walking
performance and positive effects on the arterial wall
structure and function have been described.61 Never-
theless, in our opinion, the major proven consideration
to prescribe LLA to PAOD patients is the prevention of
cardiovascular death and (recurrent) major cardiovas-
cular events such a myocardial infarction.Glucose lowering agents
Detailed analysis of prevalence of diabetes mellitus was
described in almost all evaluated studies; almost 81% of
registered diabetic patients were prescribed with GLA.
Although a substantial part of diabetics will improve blood
glucose levels by alteration of lifestyle, including weight
loss, exercise and nutrition, intensive glucose monitoring
and oral or IM medication is frequently indicated. Aggres-
sive diabetes mellitus control decreases microangiopathy
and its related complications and may decrease vascular
mortality and morbidity rates.62
Related factors of suboptimal implementation of
established recommended SP
In this systematic review, several factors were identified
causing the suboptimal SP prevalence. These factors can be
divided into patient-related, physician-related and health-
care-related factors. It is important to mention that we
summed the opinion of the authors of the articles included
in this systematic review.Patient-related factors
First, it is relevant that patients understand the threat of
the disease, which depends on their perception of its
seriousness and their own susceptibility.24,26,32,35 The
patient should clearly understand the dose, frequency,
timing and duration of SP. Patients want to be regarded as
sophisticated and sceptical clients and need proper infor-
mation so that they can be involved in health-care
decisions.63
Second, another potential cause that contributes to the
lower rates of SP for PAOD patients could be the lack of
patient compliance to prescription medication.32 Patient-
related factors for non-compliance appear to be younger
age, smoking, lack of low fat diet and exercise.64 To
improve compliance, physicians should discuss compliance
with their patients at every visit in a non-judgemental
manner and should also communicate their respect for the
patient’s perspective on his/her condition.65 To increase
patient compliance, regular and frequent scheduled
outpatient visits, contacts via telephone and follow-up by
mail using an automatically generated prescription-
reminder chart will result in a practical and cost-effective
aid to compliance.66,67
Third, polypharmacy because of co-existing cardiovas-
cular RFs results in the patients’ non-compliance with
newly prescribed medications.32 Increased numbers of
cardiovascular drugs per patient brings about a decreased
preference for a specific drug64 and improper use.68Physician-related factors
First, inadequate recognition and underdiagnosis of PAOD
due to deficiencies in physician knowledge contribute to
a lower rate of atherosclerotic RF reduction in patients
with PAOD Primary care physicians usually do not conduct
a full vascular RF profile with subsequent SP.65
Second, in this systematic review, the main cause of
suboptimal SP in PAOD patients is the lack of physicians’
knowledge of RF modification in this specific patient
population. 16,20,21,23e30,33e35,37 This finding is in accor-
dance with several reports described in the literature69e72
concluding that deficiencies in physician knowledge
contribute to lower rates of RF reduction and SP for PAOD
patients. These studies reveal that physicians’ perceptions
towards risk reduction in PAOD identify glaring knowledge
and action gaps, despite the overwhelming recognition that
recommending and instituting therapy should be the
responsibility of the physician. With the suboptimal
utilisation rate of SP, only one-fourth of the participants
rated their knowledge about risk reduction as aboveaverage.
Third, it is important to realise that most of the physi-
cians lack time for a structured and repetitive SP for each
PAOD patient in the outpatient clinic and/or during
admission for PAOD treatment.20,24,32 Time is simply too
scarce for a structured history evaluation, complete
physical examination, laboratory and duplex ultrasound
evaluation. Furthermore, evaluation of implemented SP
during follow-up is often too time consuming.
Fourth, the lack of reimbursement for RF assessment in
PAOD patients may be an important barrier to effective SP
in PAOD.26 Re-evaluation in the outpatient clinic is time
consuming and without direct reimbursement for this
process, it is most easily disregarded. Without direct
reimbursement for these preventative strategies,
a decreased interest or responsibility for the actual SP in
these high-risk patients can be expected.
Health-care-related factors
The responsibility for SP of patients with PAOD is spread out
across a number of specialties. Many of the PAOD patients
with extensive co-morbidity have been treated by a variety
of specialists such as cardiologists, diabetologists, internal
medicine, stroke physicians and vascular surgeons,
depending on their co-morbidities.19,20,31,32,36,37,39
Although all these physicians have an important role in the
treatment of specific signs and symptoms of the PAOD
patient, a co-ordination of SP is frequently lacking.Suggestions for optimising the implementation of
established recommended SP
The message is evident, clear and alarming; therefore, it
becomes even more important to find ways to improve SP.
Computer analysis database system
We composed a user-friendly computer analysis database
system for vascular patients in daily practice. Such an
integrated health-care system with electronic medical
records and communication could represent a viable model
of comprehensive care whereby vascular specialists could
Secondary Prevention, PAOD 79initiate changes and interactively communicate to primary
physicians and pharmacists during follow-up (Appendix 6).
Multidisciplinary meeting
We propose the implementation of a standardised multi-
disciplinary approach with all specialists conferring with
the PAOD patient; this can result in improvement of
quality of care.73 The aim of this meeting is reducing
patient morbidity and mortality and to strive for the
highest possible quality of care by optimising the imple-
mentation of established recommended SP in patients
with PAOD.
Limitations
Some limitations of our study should be mentioned. First,
publication bias for studies reporting on evaluation of SP
limits conclusions from this outcome. All studies, included
reporting prevalence of SP in patients suffering from PAOD,
are considered to be centres with specific focus on this
topic. Therefore, SP in these centres is more likely to
implement recent guidelines than centres without this
preventative aim. So, actual SP in today’s medicine is
probably less implemented than in evaluated literature.
Second, the literature search resulted in a large number of
case series containing small numbers of patients. We
excluded series with less than 40 patients, and, as a result,
some data may have been lost from the systematic review.
Third, in some of these reports, clear definitions of SP
concerning APA, LLA, HRLA and BPLA are lacking, whichAppendix 1
The PubMed search strategy.
(‘‘secondary prevention’’ OR ‘‘secondary medical prevention’’ OR
OR ‘‘risk factor management’’ OR ‘‘risk factor modification’’ OR ‘‘
factors treatment’’ OR ‘‘risk factors modification’’ OR ‘‘risk fact
control’’ OR ‘‘risk factor profile’’ OR ‘‘risk factor profiles’’ OR ‘‘
‘‘modifiable risk factors’’ OR ‘‘modifiable risk factor’’ OR ‘‘seco
‘‘medical management’’ OR cardioprotect*[ti] OR ‘‘Angiotensin-C
Converting Enzyme Inhibitors’’[ti] OR ‘‘Receptors, Angiotensin’’[
agents’’[ti] OR ‘‘Platelet Aggregation Inhibitors’’[majr] OR ‘‘anti
‘‘Antilipemic Agents’’[majr] OR ‘‘lipid lowering’’[ti] OR beta-blo
Antagonists’’[majr] OR ‘‘calcium channel blockers’’[mesh] OR ‘‘c
Agents’’[majr] OR ‘‘Physician’s Practice Patterns’’[majr] OR ‘‘me
‘‘medical therapies’’[ti] OR ‘‘tobacco use’’[ti] OR smoking[ti] OR
‘‘Tobacco Use Cessation’’[majr] OR ‘‘exercise treatment’’[ti] OR
AND (‘‘Peripheral Vascular Diseases’’[Majr:NoExp] OR ‘‘periphera
arteriosclerosis[ti] OR Arteriolosclerosis[ti] OR ‘‘Arteriolosclerosi
[majr] OR ‘‘Intermittent Claudication’’[majr] OR ‘‘Intermittent C
extremity’’[tw] OR ‘‘lower extremities’’[tw] OR ‘‘lower limb’’[tw
[mesh:NoExp] OR foot OR feet OR leg OR legs)) OR ‘‘peripheral a
[tiab] OR ‘‘peripheral arterial diseases’’[tiab] OR ‘‘critical lower
critical lower limb ischaemic OR critical lower limb ischemic ORmay have confounded our review. Fourth, the number of
prospective studies was relatively low, which makes inter-
pretation of these results difficult. We tried to reduce the
large degree of clinical heterogeneity by defining strict
inclusion criteria.
Conclusion
Our study provides current evidence that the SP of
patients with PAOD still needs improvement. This is
disappointing given international efforts to increase the
awareness and profile of this condition. We have found
that despite clear guidelines for the medical community
regarding cardiovascular prevention, a large percentage
of patients with PAOD are not receiving appropriate SP for
their co-morbidities or are not meeting the established
goals with only a minority of patients at target goals. In
our opinion, reasons for this disparity may include
patient-related factors, physician-related factors and
health-care-related factors. We are of the opinion that to
rectify this suboptimal SP, there is a need for increased
physician awareness of PAOD, reimbursement and imple-
mentation of screening programmes and more aggressive
treatment of RFs.
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study.‘‘risk factors’’[majr] OR ‘‘risk factors’’[ti] OR ‘‘risk factor’’[ti]
risk factors management’’ OR ‘‘risk factor treatment’’ OR ‘‘risk
or control’’ OR ‘‘risk factors
risk factors profile’’ OR ‘‘risk factors profiles’’ OR
ndary risk factor’’ OR ‘‘secondary risk factors’’ OR
onverting Enzyme Inhibitors’’[majr] OR ‘‘Angiotensin-
majr] OR ‘‘Angiotensin Receptors’’[ti] OR ‘‘antiplatelet
hypertensive agents’’[majr] OR antihypertensive[ti] OR
cker[ti] OR beta-blockers[ti] OR ‘‘Adrenergic beta-
alcium channel blockers’’[ti] OR ‘‘Cardiovascular
dical treatment’’[ti] OR ‘‘medical therapy’’[ti] OR
‘‘smoking’’[majr] OR ‘‘smoking cessation’’[majr] OR
‘‘exercise therapy’’[majr] OR ‘‘exercise therapy’’[ti])
l vascular’’[ti] OR ((‘‘Arteriosclerosis’’[Majr:NoExp] OR
s’’[majr] OR Atherosclerosis[ti] OR ‘‘Atherosclerosis’’
laudication’’[ti] OR atherosclerotic[ti]) AND (‘‘lower
] OR ‘‘lower limbs’’[tw] OR ‘‘Lower Extremity’’
rterial occlusive’’[tiab] OR ‘‘peripheral arterial disease’’
limb ischaemia’’ OR ‘‘critical lower limb ischemia’’ OR
(ischemia AND lower extremity))
Appendix 2
The Cochrane Library search strategy.
#1 ‘‘secondary prevention’’ OR ‘‘secondary medical prevention’’ OR ‘‘risk factor management’’ OR ‘‘risk factor modification’’ OR ‘‘risk
factors management’’ OR ‘‘risk factor treatment’’ OR ‘‘risk factors treatment’’ OR ‘‘risk factors modification’’ OR ‘‘
risk factor control’’ OR ‘‘risk factors control’’ OR ‘‘risk factor profile’’ OR ‘‘risk factor profiles’’ OR ‘‘risk factors profile’’ OR
‘‘risk factors profiles’’ OR ‘‘modifiable risk factors’’ OR ‘‘modifiable risk factor’’ OR ‘‘secondary risk factor’’ OR ‘‘secondary
risk factors’’ OR ‘‘medical management’’ :ti,ab,kw
#2 ‘‘risk factors’’ OR ‘‘risk factor’’ OR cardioprotect* OR ‘‘Angiotensin-Converting Enzyme Inhibitor’’ OR ‘‘Angiotensin-Converting
Enzyme Inhibitors’’ OR ‘‘ace-inhibitor’’ OR ‘‘ace-inhibitors’’ OR ‘‘angiotensin receptor’’ OR ‘‘Angiotensin Receptors’’ OR
‘‘antiplatelet agents’’ OR ‘‘Platelet Aggregation Inhibitors’’ OR ‘‘Platelet Aggregation Inhibitor’’ OR antihypertensive OR
Antilipemic OR ‘‘lipid lowering’’ OR beta-blocker OR beta-blockers OR ‘‘Adrenergic beta-Antagonists’’ OR ‘‘Adrenergic beta-
Antagonist’’ OR ‘‘calcium channel blocker’’ OR ‘‘calcium channel blockers’’ OR ‘‘Cardiovascular Agent’’ OR ‘‘cardiovascular
agents’’ OR ‘‘medical treatment’’ OR ‘‘medical therapy’’ OR ‘‘medical therapies’’ OR tobacco OR smoking OR ‘‘exercise
treatment’’ OR ‘‘exercise therapy’’:ti
#3 MeSH descriptor Physician’s Practice Patterns explode all trees
#4 (#1 OR #2 OR #3)
#5 ‘‘peripheral vascular’’: ti
#6 ((Arteriosclero* OR Arteriolosclero* OR Atherosclero* OR ‘‘Intermittent Claudication’’) AND (‘‘lower extremity’’ OR ‘‘lower
extremities’’ OR ‘‘lower limb’’ OR ‘‘lower limbs’’ OR foot OR feet OR leg OR legs)): ti,ab,kw
#7 ‘‘peripheral arterial occlusive’’ OR ‘‘peripheral arterial disease’’ OR ‘‘peripheral arterial diseases’’ OR ‘‘critical lower limb
ischaemia’’ OR ‘‘critical lower limb ischemia’’ OR ‘‘critical lower limb ischaemic’’ OR ‘‘critical lower limb ischemic’’ OR
(ischemia AND lower extremity): ti,ab,kw
#8 (#5 OR #6 OR #7)
#9 (#8 AND #4)
Appendix 3
The EMBASE search strategy.
secondary prevention/ OR secondary prevention.mp OR secondary medical prevention.mp OR *risk factor/ OR risk factor.ti OR
risk factors.ti OR risk factor management.mp OR risk factor modification.mp OR risk factor treatment.mp OR risk
factors treatment.mp OR risk factors modification.mp OR risk factor control.mp OR risk factors control OR risk factor
profile.mp OR risk factor profiles.mp OR risk factors profile.mp OR risk factors profiles.mp OR modifiable risk factors.
mp OR modifiable risk factor.mp OR secondary risk factor.mp OR secondary risk factors.mp OR medical management.
mp OR cardioprotect$.ti OR *Dipeptidyl Carboxypeptidase Inhibitor/ OR Angiotensin-Converting Enzyme Inhibitors.ti OR
*angiotensin receptor/ OR angiotensin receptor.ti OR angiotensin receptors.ti OR *Antithrombocytic Agent/ OR antiplatelet
agent.ti OR antiplatelet agents.ti OR Antithrombocytic agent.ti OR Antithrombocytic agents.ti OR platelet aggregation
inhibitors.ti OR *antihypertensive agent/ OR antihypertensive.ti OR *Antilipemic Agents/ OR lipid lowering.ti OR *Beta
Adrenergic Receptor Blocking Agent/ OR beta-blocker.ti OR beta-blockers.ti OR beta-blocker.ti OR beta-blockers.ti OR
*calcium channel blocking agent/ OR calcium channel blocker$.ti OR *cardiovascular agent/ OR *tobacco dependence/ OR
tobacco abuse.ti OR *smoking/ OR *smoking cessation/ OR *kinesiotherapy/ OR exercise treatment.ti OR exercise therapy.
ti OR exercise therapies.ti OR medical treatment.ti OR medical therapy.ti OR medical therapies.ti AND (*Peripheral
Vascular Disease/ OR peripheral vascular.ti) OR ((*Arteriosclerosis/ OR arteriosclerosis.ti OR Arteriolosclerosis.ti OR
*Arteriolosclerosis/ OR Atherosclerosis.ti OR *Atherosclerosis/ OR *Intermittent Claudication/ OR Intermittent
Claudication.ti. OR atherosclerotic.ti) AND (*leg/ OR lower extremity.ti OR lower extremities.ti OR lower limb.ti OR lower
limbs.ti OR Lower Extremity.ti OR *foot/ OR foot.ti OR feet.ti OR leg.ti OR legs.ti)) OR exp *peripheral occlusive artery
disease/ OR peripheral occlusive artery.ti OR peripheral occlusive arteries.ti OR peripheral arterial disease.ti OR
peripheral arterial diseases.ti OR (*limb ischemia/ AND (leg/ OR lower extremity.mp OR lower extremities.mp OR lower
limb.mp OR lower limbs.mp OR Lower Extremity.mp OR foot/ OR foot.mp OR feet.mp OR leg.mp OR legs.mp)) OR (lower
limb ischaemia.ti OR lower limb ischemia.ti OR *leg ischemia/ OR leg ischemia.ti OR leg ischaemia.ti)
80 H.C. Flu et al.
Appendix 4
The Web of Science search strategy.
(ts[(‘‘secondary prevention’’ OR ‘‘secondary medical prevention’’ OR ‘‘risk factor management’’ OR ‘‘risk factor modification’’
OR ‘‘risk factors management’’ OR ‘‘risk factor treatment’’ OR ‘‘risk factors treatment’’ OR ‘‘risk factors modification’’ OR ‘‘risk
factor control’’ OR ‘‘risk factors control’’ OR ‘‘risk factor profile’’ OR ‘‘risk factor profiles’’ OR
‘‘risk factors profile’’ OR ‘‘risk factors profiles’’ OR ‘‘modifiable risk factors’’ OR ‘‘modifiable risk factor’’ OR ‘‘secondary
risk factor’’ OR ‘‘secondary risk factors’’ OR ‘‘medical management’’) OR TI[(‘‘risk factor*’’ OR cardioprotect* OR ‘‘
Angiotensin-Converting Enzyme Inhibitor*’’ OR ‘‘ACE-inhibitor*’’ OR ‘‘Angiotensin Receptor*’’ OR antiplatelet OR ‘‘Platelet
Aggregation Inhibitor*’’[ti] OR antihypertensive OR antilipemic OR ‘‘lipid lowering’’ OR ‘‘beta-blocker*’’ OR ‘‘Adrenergic
beta-Antagonist*’’ OR ‘‘calcium channel blocker*’’ OR ‘‘Cardiovascular Agent*’’ OR ‘‘medical treatment’’ OR ‘‘medical
therapy’’ OR ‘‘medical therapies’’ OR ‘‘tobacco use’’ OR smoking OR ‘‘exercise treatment’’ OR ‘‘exercise therapy’’))
AND
((TI[‘‘peripheral vascular’’) OR (ti[ (arteriosclero* OR Arteriolosclero* OR atherosclero* OR ‘‘Intermittent Claudication’’)
AND ts[(‘‘lower extremit*’’ OR ‘‘lower limb*’’ OR foot OR feet OR leg OR legs)) OR ts[(‘‘peripheral arterial occlusive’’
OR ‘‘peripheral arterial disease*’’ OR ‘‘critical lower limb isch*’’))
Appendix 5
Inclusion criteria.
 Symptomatic PAOD according to the SVS/ISCVS guidelines40
- Intermittent claudication
- Critical limb ischaemia
 Secondary prevention measures
- Antiplatelet agents (APA) defined as the prescription of antiplatelet agents (acetylsalicylic acid, dipyridamole or clopidogrel)
- Lipid lowering agents (LLA) defined as the prescription of agents used to treat lipid abnormalities (statins)
- Heart rate lowering agents (HRLA) defined as the prescription of heart rate lowering agents (b-blockers)
- Blood pressure lowering agents (BPLA) defined as the prescription of antihypertensive medications (angiotensin-converting
enzyme inhibitors, and/or calcium channel blockers, angiotensin II receptor blockers and/or diuretics)
- Glucose lowering agents (GLA) defined as the current use of diabetes medications (insulin and oral hypoglycemic agents)
 Treatment
- Conservative
- Revascularization (endovascular / surgical)
- Major amputation (below knee amputation / above knee amputation)
- Control after invasive treatment
 Period
- After initiation of the TASC I guidelines 13
 Patient series
- Original
- Consecutive
 Evaluating
- Implementation of established recommended secondary prevention in patients with PAOD
 Language
- English
- French
- Dutch
- German
 Total patients
- Ccomprise a minimal number of forty patients
PAODZ Peripheral Arterial Occlusive Disease; SVS/ISCVSZ Society of Vascular Surgery / North American Chapter of the
International Society for Cardiovascular surgery; TASCZ Trans-Atlantic Inter-Society Consensus Document on
Management of Peripheral Arterial Disease.
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Appendix 6a
Example of the ‘medication screen’ of the recommended computer analysis database system to be used in a real time
electronic file for patients diagnosed with PAOD. Important to stress is that the registered information in this appendix does
not contain actual patient information, it is all made-up.
Appendix 6b
Example of the ‘laboratory screen’ of the recommended computer analysis database system to be used in a real time
electronic file for patients diagnosed with PAOD. Important to stress is that the registered information in this appendix does
not contain actual patient information, it is all made-up.
HDLZ high density lipoprotein; LDLZ low density lipoprotein; HgbA1CZ hemoglobin-A1C; POSSUMZ Physiological and
Operative Severity Score for the enumeration of Mortality and morbidity. HgbZ haemoglobin; HtZ haematocrit; aPTT -
Z activated partial thromboplastin time; PTZ prothrombin time; INRZ international normalized ratio.
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Appendix 6c
Example of the ‘laboratory screen’ of the recommended computer analysis database system to be used in a real time
electronic file for patients diagnosed with PAOD. Important to stress is that the registered information in this appendix does
not contain actual patient information, it is all made-up.
PTCAZ percutaneous transluminal coronary angioplasty; CABGZ coronary artery bypass grafting; NYHAZNew York Heart
Association; SVS/ISCVSZ Society of Vascular Surgery / North American Chapter of the International Society for Cardiovascular
surgery; ASAZ American Society of Anaesthesiologists; POSSUMZ Physiological and Operative Severity Score for the enumer-
ation of Mortality and morbidity; TIAZ transient ischaemic attack; CASZ carotid artery stenting; CEAZ carotid endarterec-
tomy; pckyrsZ pack years; WHO/ISHZworld health organization/ International Society of Hypertension; NCEPZ national
cholesterol education Program; GOLDZGlobal Initiative for Chronic Obstructive Lung Disease; NKF-DOQIZNational Kidney
Foundation Disease Outcome Quality Initiative;GCSZ glascow coma scale; ECGZ electrocardiogram.
Appendix 6d
Example of the ‘clinical risk evaluation screen’ of the recommended computer analysis database system to be used in a real
time electronic file for patients diagnosed with PAOD. Important to stress is that the registered information in this appendix
does not contain actual patient information, it is all made-up.
APAZ antiplatelet agent; ACAZ anti coagulant agent; LLAZ lipid lowering agent; GLAZ glucose lowering agent;
HRLAZ heart rate lowering agent; BPLAZ blood pressure lowering agent; BMIZ body mass index; SVS/ISCVSZ Society of
Vascular Surgery / North American Chapter of the International Society for Cardiovascular surgery; ASAZ American Society
of Anaesthesiologists; POSSUMZ Physiological and Operative Severity Score for the enumeration of Mortality and morbidity;
ECGZ electrocardiogram; ICUZ intensive care unit.
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